乳腺MRI对BI-RADS 4B类钼靶微钙化的价值:基于BI-RADS第5版
回顾性分析108例钼靶BI-RADS 4B类无肿块微钙化患者,评估乳腺MRI能否提高阳性预测值。以MRI有强化为标准,PPV从0.38(41/108)升至0.82(37/45),良性活检减少88%(59/67),但漏诊4例导管原位癌。对于区域性/成组分布的无定形微钙化,MRI可提高PPV且未漏诊恶性肿瘤。
要点
- BI-RADS 4B类微钙化加做MRI,以有强化为标准,PPV从0.38升至0.82。
- MRI有强化标准使良性活检减少88%(59/67),但漏诊4例导管原位癌。
- 区域性/成组分布的无定形微钙化,MRI提高PPV且未漏诊恶性肿瘤。
核心结论
- 乳腺MRI有潜力通过减少假阳性发现来提高BI-RADS 4B类钼靶微钙化的PPV。
研究设计与样本
- 回顾性研究,纳入2009年1月至2015年12月连续108例钼靶BI-RADS 4B类无肿块微钙化患者,均行乳腺MRI及后续组织病理学确认,按BI-RADS第5版分析影像特征。
关键影像表现/征象
- 钼靶表现为BI-RADS 4B类微钙化且无肿块。
- MRI评估强化存在与否,并分析无定形微钙化的分布(区域性/成组分布)。
诊断标准与关键数值
- 以MRI有强化为标准,PPV从0.38(41/108)升至0.82(37/45)。
- 以MRI有强化为标准,良性活检减少88%(59/67)。
- 以MRI有强化为标准,漏诊4例导管原位癌。
- 对于区域性/成组分布的无定形微钙化,MRI提高PPV且未漏诊恶性肿瘤。
临床应用与阅片要点
- 若钼靶上无定形微钙化呈区域性/成组分布且MRI无强化,作者认为可考虑随访而非立即活检。
- 乳腺MRI可能有助于指导BI-RADS 4B类微钙化的最佳活检部位。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To investigate whether magnetic resonance imaging (MRI) can improve the positive predictive value (PPV) for Breast Imaging-Reporting and Data System (BI-RADS) category 4B mammographic microcalcification.
MATERIALS AND METHODS: One hundred and eight consecutive patients with BI-RADS category 4B microcalcification without mass on mammography underwent breast MRI and subsequent histopathological confirmation between January 2009 and December 2015. Mammography and MRI findings were reviewed retrospectively, and imaging features were analysed according to the 5th edition of BI-RADS. The PPV of each descriptor was analysed to identify subgroups in which PPV could be improved by the addition of MRI.
RESULTS: When the criteria of presence of enhancement on MRI was applied to category 4B microcalcification, PPV increased from 0.38 (41 of 108) to 0.82 (37 of 45) and reduced benign biopsy results by 88% (59 of 67). Four ductal carcinoma in situ lesions were missed. For amorphous microcalcification with regional or grouped distribution, MRI images increased PPV without missing malignancy.
CONCLUSION: Breast MRI has the potential to improve PPV for category 4B mammographic microcalcification by reducing false-positive findings. If amorphous microcalcification with regional or grouped distribution on mammography shows no enhancement on MRI, follow-up could be considered rather than immediate biopsy. In addition, breast MRI might have the potential to guide the best site to biopsy in category 4B microcalcification.
引用
- Eun NL, Son EJ, Gweon HM, et al. The value of breast MRI for BI-RADS category 4B mammographic microcalcification: based on the 5th edition of BI-RADS. Clin Radiol. 2018. PMID: 29853301. doi:10.1016/j.crad.2018.04.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。